Can mirikizumab mend the gut? new trial aims for deep healing in Crohn's

NCT ID NCT07292012

Recruiting now Disease control Sponsor: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests if the drug mirikizumab can heal damage deep in the gut wall in people with Crohn's disease. About 75 adults with active symptoms and inflammation seen on MRI will receive the drug. The main goal is to see if the gut shows at least 25% improvement after 24 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE (CD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN DISEASE (CD)

Contacts and locations

Locations

CH de Valence
NOT_YET_RECRUITING

Valence, 26000, France
CHU de Brest - Hôpital de la Cavale Blanche
NOT_YET_RECRUITING

Brest, 29200, France
CHU de Clermont Ferrand - Hôpital d'Estaing
RECRUITING

Clermont-Ferrand, 63003, France
CHU de Nîmes Carémeau
NOT_YET_RECRUITING

Nîmes, 30029, France
CHU de Toulouse - Hôpital Rangueil
NOT_YET_RECRUITING

Toulouse, 31059, France
Institut Mutualiste Monsouris
NOT_YET_RECRUITING

Paris, 75674, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.